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isolated thymocytes and on thymocyte development in organ cul-
tures. We observed a dose dependent increase in the survival of
isolated day 15 fetal thymocytes. To examine the effect of rhGH in
vitro we ﬁrst developed a serum-free fetal thymic organ culture
assay to eliminate serum as an additional exogenous source of GH
and IGF-1 in the system. In fetal thymic organ cultures performed
in serum-free conditions, the addition of 10–100 ng/ml of rhGH
resulted in signiﬁcant increases in total thymic lobe cellularity,
CD4CD8, and CD4CD8 thymocytes at day 13 of fetal thy-




respectively). In contrast, the addition of 50 ng/ml rhIL-7 results
promotes survival of CD4CD8 thymocytes and exerts a block in
differentiation to CD4CD8 cells in this culture system. These
results demonstrate that promotion of thymopoiesis associated
with rhGH administration after bone marrow transplant may be
due, at least in part, by direct action of rhGH on the thymus and
thymocytes and that mechanism of action appears to differ from
IL-7.
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DEVELOPMENT OF B LYMPHOPOIESIS AFTER ALLOGENEIC STEM CELL
TRANSPLANTATION
Winkler, J.1; Biller, A.1; Roesler, W.1; Schaefer-Eckart, K.2; Wandt,
H.2; Schwerdtfeger, R.3; Holler, E.4; Winkler, T.H.5; Gramatzki, M.6
1. Division of Hematology/Oncology, University of Erlangen, Erlangen,
Germany; 2. Medical Clinic 5, Nuremberg, Germany; 3. BMT Center,
DKD Wiesbaden, Wiesbaden, Germany; 4. Department of Hematology/
Oncology, University of Regensburg, Regensburg, Germany; 5. Hema-
topoiesis Unit, University of Erlangen, Erlangen, Germany; 6. Division
of Stem Cell and Immunotherapy, 2nd Medical Department, University
of Kiel, Kiel, Germany.
Long term engraftment after stem cell transplantation is depen-
dent on pluripotent hematopoietic stem cells capable to multilin-
eage reconstitution. The engraftment and prolonged repopulation
of B lymphoid progenitor cells is dependent on pluripotent hema-
topoietic stem cells. Recently, we could demonstrate that a high
number of B cell progenitors are detectable in the bone marrow
from patients both after allogeneic PBSCT and after allogeneic
BMT. The percentage of CD19CD10 cells pro-B/pre-B cells
showed a high variability and ranged from 0 to 98% of all B
lymphocytes. No statistical difference of precursor B lymphocytes
between BM recipients and PBSC recipients was found. In micro-
satellite analysis, both in PBSC recipients and in BM recipients the
B cell precursors were derived exclusively from the donor. The aim
of the study was to identify predictors of B lymphopoiesis in the
bone marrow after stem cells transplantation. A stepwise, multiple
regression analysis was performed. The stem cell source, BM or
PBSC, the occurrence of GVHD, the conditioning with TBI and
the immunosuppression with ATG were entered as categorical
variables, whereas the BM collection time after transplantation, the
age of the donor and of the recipient, the transplanted stem cell
quantity and the T cell content of the BM sample served as
continuous variables. The time elapsed after transplantation when
BM was collected (p0.002) as well as severe GVHD (aGVHD
grade III/IV or extensive cGVHD) at the time point of sample
analysis (p0.036) were identiﬁed as parameters with an indepen-
dent inﬂuence on the percentage of B cell precursors. The highest
percentage of precursor B cells was found during the ﬁrst year after
transplantation. However, patients with severe GVHD showed the
lowest percentage of precursor B cells. The hyperactive B lympho-
poiesis in the ﬁrst year after transplantation was in contrast to the
low number of circulating B cells. In addition, these studies show,
that G-CSF mobilized PBSC contain sufﬁcient hematopoietic
stem cells capable of long term reconstitution of the B cell com-
partment.
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MAJOR CYTOTOXIC PATHWAYS ARE REQUIRED FOR EFFECTIVE RESIS-
TANCE AGAINST HEMATOPOIETIC ALLOGRAFTS BY EFFECTOR CELLS
DERIVED FROM NAI¨VE BUT NOT MEMORY RECIPIENT T CELLS
Zimmerman, Z.F.; Levy, R.B. University of Miami School of Medicine,
Miami, FL.
T cell mediated resistance to engraftment must be prevented
following clinical BMT particularly after T cell depletion and
reduced intensity conditioning. Following sensitization to donor
alloantigen, mice deﬁcient in perforin and FasL (B6-cdd) mount a
vigorous T cell mediated resistance to high numbers of donor BM,
despite the simultaneous blockade/absence of TRAIL, TL1a,
TWEAK, and TNFR1. We are investigating host cytotoxic path-
ways post-BMT to determine if their signiﬁcance differs depend-
ing on whether effector cells are derived from naı¨ve or memory T
cell populations. An ex-vivo model of T effector cell-PC interaction
was developed to address this issue. BM cells were cultured with in
vitro generated effector cells in the presence of SCF, TPO, and
Flt3L for 48 hrs. and then assessed for remaining CFU-GM levels.
Unsensitized B6-wt or B6 cdd spleen/LN cells were stimulated
against H-2d alloantigens. Effector cells from B6-wt or B6-cdd
anti-BALB.B cell lines initiated from antigen sensitized mice were
utilized as a memory-like population. No population inhibited
syngeneic B6 BM CFU activity. BALB/c CFU activity was mark-
edly diminished following incubation with B6-wt effectors but was
not diminished following co-culture with B6-cdd effectors. In
marked contrast, when effector cells from B6-wt and B6-cdd cell
lines were examined, both populations speciﬁcally and profoundly
inhibited BALB.B CFU-GM activity. These latter results are con-
sistent with our ﬁndings reporting strong BMT resistance in situ in
cytotoxically normal and defective sensitized recipients. To begin
addressing the role of cytotoxicity in resistance by effector cells
derived from naı¨ve T cells in vivo, MHC identical C3H.SW BM
was transplanted into cytotoxically normal or defective non-my-
eloablatively (5.5 TBI) conditioned recipients. Preliminary ﬁnd-
ings indicate that “naı¨ve” B6-perforin deﬁcient and B6 CD95L
defective recipients maintain their capacity to rigorously reject
allogeneic BM grafts, however, resistance in B6-cdd mice is weak-
ened. Moreover, failure to reject allogeneic bcl-2 tg BM in non-
donor sensitized recipients supports a requirement for cytotoxic
function by effector T cells derived from naı¨ve T cells. In total,
these data are consistent with the notion that resistance mediated
by effector cells derived from memory—but not naı¨ve—T cells
does not require a contribution by major cell-mediated cytotoxic
pathways.
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EX VIVO GENERATED MYELOID PROGENITORS PROTECT MICE FROM
LETHAL IRRADIATION
Christensen, J.L.; Smith, S.; Gille, D.; Domen, J.; Danenberg, E.;
Wahedi, M.; Fong, T. Cellerant Therapeutics, Palo Alto, CA.
We are investigating the potential application of human myeloid
progenitors (MP) as a novel therapy to enhance immune functions
and provide temporary hematopoietic recovery for victims who are
exposed to life-threatening doses of radiation or high-dose chem-
ical or radio-myeloablation as component of their medical treat-
ment. The myeloid progenitor pool, in both mouse and human
bone marrow, has been characterized using cell surface markers.
Myeloid progenitors include Common Myeloid Progenitors
(CMP), Granulocyte Macrophage Progenitors (GMP) and
Megakaryocyte Erythroid Progenitors (MEP). The CMP and
MEP have been found to provide radioprotection in a syngeneic
mouse model [J Clin Invest. 109:1579–85 (2002)]. We are exam-
ining whether MP also have radioprotective qualities in an alloge-
neic transplantation model. Myeloid progenitors were either
sorted from mouse bone marrow (CD117, CD90.1, Linneg/low
Sca-1) or derived in culture from puriﬁed KTLS mouse HSC
(CD117, CD90.1low, Linneg/low Sca-1). Sorted MPs provide
good radioprotection in the syngeneic and matched unrelated
transplantation settings. While sorted MPs provide only limited
protection in an allogeneic model, progenitors derived ex vivo
protect allogeneic recipients from radiation induced death. The
added burden of opportunistic infection often complicates recov-
ery during periods of neutropenia. MPs have also been shown to
provide protection against otherwise lethal fungal infections in
neutropenic mice [Blood 100:4660–7 (2002)]. We are determining
if cultured derived MP provide protection from both hematopoi-
etic failure and fungal infection. This research is aimed at devel-
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oping a bridging therapy suitable for treating large numbers of
people exposed to high doses of ionizing irradiation. These pre-
clinical experiments indicate that allogeneic MP generated from
puriﬁed HSC by ex vivo expansion can function as a bridging





KERATINOCYTE GROWTH FACTOR (KGF) IS REQUIRED FOR POST-
NATAL THYMIC REGENERATION
Alpdogan, O.1; Hubbard, V.M.1; Muriglan, S.J.1; Goldberg, G.L.2;
Kochman, A.A.1; Eng, J.M.1; Smith, O.M.1; Boyd, R.L.2; van den
Brink, M.R.M.1 1. Memorial Sloan-Kettering Cancer Center, New
York, NY; 2. Monash University, Melbourne, Victoria, Australia.
KGF is a ﬁbroblast growth factor family member (FGF-7) that
mediates epithelial cell proliferation and differentiation in a variety
of tissues. Recent pre-clinical studies have demonstrated that KGF
administration (before conditioning) to the recipients of allogeneic
bone marrow transplantation (BMT) can enhance T cell and thy-
mic reconstitution. Therefore, we studied the role of KGF on T
cell development by using KGF (/) mice in experimental mu-
rine models. Phenotypic analysis of KGF (/) mice at varying
ages (6–44 weeks) demonstrated that the bone marrow, thymus
and lymph node cellularity and the cell distribution, as well as
thymic stromal cell composition among KGF (/), wild type
(WT) and KGF (/) mice were similar. However, splenic cellu-
larity and splenic T cell numbers were slightly lower than WT and
KGF (/) controls. More importantly, KGF (/) mice had a
greater than six fold decrease in thymic cellularity after sublethal
irradiation (450 cGy), while erythroid, myeloid and platelet recov-
ery were intact. In our preliminary experiments the analysis of
thymic stroma revealed that ﬁbroblast numbers were decreased in
KGF (/) compared to controls following sublethal irradiation.
We used bone marrow transplantation models to assess the relative
contribution of KGF produced by thymocytes or thymic stromal
cells during thymic regeneration after irradiation. T cell reconsti-
tution was impaired in syngeneic or allogeneic KGF (/) BMT
recipients in comparison to KGF (/) controls but there was no
difference in the distribution of thymocyte subsets or splenic T cell
content. The recipients of KGF (/) bone marrow had decreased
thymic and splenic cellularity after allogeneic BMT. These data
demonstrate that both donor and host derived KGF play a role in
thymic regeneration. Finally, rhKGF (palifermin) administration
to young and old mice (10 month old) enhanced thymopoiesis
when analyzed 28 days after rhKGF (palifermin) administration.
Pre-BMT rhKGF (palifermin) administration to the recipients of
syngeneic and allogeneic BMT also resulted in a 2–6 fold increase
in thymic cellularity compared to the control group. We conclude
that KGF produced by both thymocytes and thymic stromal cells
is not required for pre- and post-natal thymic development, but
plays a role in post-natal thymic stroma regeneration after irradi-
ation. These data support the potential use of KGF to protect or
restore thymic damage after chemo/radiotherapy.
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IN VIVO DUAL MODALITY CONTEMPORANEOUS IMAGING OF DIFFER-
ENT TUMOR REACTIVE T-CELL SUBPOPULATIONS
Doubrovin, M.M.; Doubrovina, E.S.; Cai, S.; Blasberg, R.G.; O’Reilly,
R.J. Memorial Sloan-Kettering Cancer Center, New York, NY.
Background: Identiﬁcation of the in vivo functions of T-cell
subpopulations in vivo is critical for understanding their interac-
tions in the course of adoptive immune cell therapy. The quanti-
tation of T-cell subpopulations in tissues would also allow for the
assessment of the proliferation potential of these cells. Previously,
we have used various applications of HSV1-tk PET and ﬁreﬂy
Luciferase reporter gene imaging for the generation of cell traf-
ﬁcking images. We have combined these two imaging options to
assess CD4 and CD8 T-cell populations and to correlate cell
numbers and image intensity using microPET and bioluminescent
imaging (BLI). Methods: Cytotoxic T-lymphocytes stably trans-
duced with reporter genes (CTL-TGN or CTL-FLucN) were
administered to NOD-SCID mice bearing previously established
subcutaneous EBV-BLCL xenografts in a dose range from 104 to
107 cells, locally. In vivo imaging of these T-cells either prelabeled
in vitro with [18F]FEAU and D-Luciferine or in vivo by intravenous
infusion of the same probes with microPET and BLI was per-
formed 4 hours after CTL injection. T-cells in post mortem tissue
samples were quantitated by FACS. The radioactivity was also
measured in these samples using gamma-counter. Total activity
obtained from 3-dimensional ROIs for microPET and total pho-
ton ﬂux measured in 2D-ROIs for BLI were used to draw dose-
calibration curves. Results: The values of T-cell retention in
tumor following a direct injection obtained for ex vivo labeled cells
were applied for correction of in vivo labeling results. For both ex
vivo and in vivo labeled T-cells, close correlations between CD8
CTL-TGN number and accumulated radioactivity (nCi/cc for
MicroPET) and between CD4 CTL-FLucN number and BLI
signal intensity expressed as a total photon ﬂux (photon/sec for
BLI) were observed. The limits of sensitivity for both BLI and
MicroPET imaging appeared to be comparable at a depth in tissue
of 7–10 mm (depth of CTL administration), approximating 105
cells. The correlations calculated between the number of CTLs
(dose) and signal intensity were used to build a scale for the
assessment of the cell number and concentration in tissues. Con-
clusions:Dual modality imaging can be used for contemporaneous
quantitative imaging of different T-cell subpopulations after adop-
tive cell therapy using noninvasive in vivo reporter gene-based
imaging techniques, such as MicroPET and BLI.
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ELIMINATION OF ALLOREACTIVE T LYMPHOCYTES USING PHOTODY-
NAMIC THERAPY PREVENTS THE DEVELOPMENT OF GVHD AND PRO-
MOTES B AND T CELL RECONSTITUTION AFTER MHC-MISMATCHED
TRANSPLANTATION
Sidi Boumedine, R.1; Krosl, G.1; Vaillancourt, M.2; Perreault, C.1; Roy,
D.C.1 1. Hopital Maisonneuve-Rosemont, Montreal, QC, Canada; 2.
Celmed BioSciences, Montreal, QC, Canada.
Previous studies have demonstrated that photodynamic therapy
can be used to eliminate alloreactive T cells and preserve graft-
versus-leukemia activity in the context of major histocompatibility
complex (MHC) mismatched stem cell transplantation (SCT).
However, the speciﬁcity of the T cell activation process and the
capacity of PDT to promote rapid immune reconstitution has not
been evaluated extensively. The purpose of this study was to de-
termine the capacity of PDT to speciﬁcally target antigen-primed
T lymphocytes and to promote B and T cell post-transplant re-
covery. C57BL/6 donor (B6; H-2b) spleen cells were ﬁrst activated
against C3H/HeJ (C3H; H-2k) host spleen cells in a one-way
mixed lymphocyte culture and then exposed to photodynamic
treatment (PDT) using dibromorhodamine methyl ester
(TH9402) as photosensitizer. Activated (CD25) T cells retained
greater concentrations of the photosensitizer and were preferen-
tially eliminated over resting lymphocytes. When lethally irradi-
ated C3H mice were transplanted with B6 bone marrow cells
supplemented with B6 spleen cells activated against C3H targets,
they rapidly succumbed to acute GVHD (within 10–47 days). In
contrast, when donor (B6) T cells were activated against C3H cells
and then exposed to PDT, 80% of C3H recipients survived (100
days) (p
0.0001). Interestingly, PDT also abrogated (100% sur-
vival) the lethal effect of the same grafts on B10BR (H-2k) recip-
ients (p
0.0001), conﬁrming the importance of the activation step
and the speciﬁcity of the PDT process for anti-H-2k primed cells.
Additionally, transplantation of PDT treated B6 T cells induced
lethal GVHD in histo-incompatible Balb/c mice (H-2d), suggest-
ing that PDT spared resting T lymphocytes for anti-non-host
reactivity. Analysis of immune recovery at day 100, evaluating T
and B cell populations in thymus and spleen, activated T cells
components (CD44, CD62L, CD69), proliferative responses (anti-
CD3 and conA), and V-repertoire indicated that T and B cell
reconstitution in MHC-mismatched mice transplanted with
primed cells exposed to PDT was similar to that of mice trans-
planted with treated or control autologous cells, demonstrating
that immune cells were preserved and functional. These results
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